1. Emerging Data and Clinical Advances in MS:

3. Goals

4. Disclaimers

5. Speaker: Stephen Krieger, MD

6. CombiRx: Relapse Activity

7. CombiRx: MRI Outcomes

8. Teriflunomide: TOWER Study

9. Daclizumab: SELECTION Trial

10. Speaker: Robert C. Bermel, MD

11. Vitamin D Status in Optic Neuritis

12. Microcystic Macular Edema

13. Biomarkers - Antibodies

14. Biomarkers - MRI

15. Speaker: Amy Perrin Ross, APRN, MSN

16. Pregnancy Outcomes: Teriflunomide

17. Teriflunomide in Men

18. Interferon β-1a Registry

19. Natalizumab Registry

20. Other Agents

21. Counseling Patients

22. Predicting Adherence

23. Key Points

24. Speaker: Timothy L. Vollmer, MD

25. Cognitive Reserve

26. Cognition in MS

27. Cognitive Issues in Children

28. Cognitive Dysfunction and MRI

29. Cognition in MS: Other Issues

30. Looking Ahead

31. Abbreviations

32. References

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)